Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 812

National Institute for Health and Care Excellence (NICE)
Record ID 32018011854
English
Details
Project Status: Completed
Year Published: 2022
URL for published report: https://www.nice.org.uk/guidance/ta812
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: England
MeSH Terms
  • Lung Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Pyrazoles
  • Pyridines
  • Pyrimidines
  • Antineoplastic Agents
Contact
Organisation Name: National Institute for Health and Care Excellence
Contact Address: Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name: nice@nice.nhs.uk
Contact Email: nice@nice.nhs.uk
Copyright: National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.